As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The Danish drugmaker will start selling a pill version of its Wegovy weight-loss medicine in January, after [securing ...

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.

U.S. regulators this week gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) formally approved Wegovy® pills, marking a major milestone ...

Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read ...

Appetite-suppressing GLP-1 tablets become accessible in January, and manufacturers and fast-food eateries may be pushed to alter more of their goods.

Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.

For the millions of Americans navigating the booming landscape of weight loss medications, the weekly injection routine just ...

Novo Nordisk's Wegovy pill is the first oral GLP-1 receptor agonist approved for weight management, offering a new treatment ...